Abstract 12038: Dual Anti-Inflammatory Effect of Simvastatin or Pioglitazone on Inflammatory Markers of Plasma and Epicardial Adipose Tissue in Coronary Patients with Metabolic Syndrome
Background: Evidences suggest that inflammatory cytokines and macrophages accumulate in Epicardial Adipose Tissue (EAT) in coronary patients (CAD) and promote atherosclerosis progression. Although Pioglitazone (P) and Simvastatin (S) reduce the plasma inflammation, their effects upon EAT in CAD patients with Metabolic Syndrome (MS) are unknown.
Objectives: To correlate inflammatory markers in EAT and high sensitivity C-reactive protein (hsCRP) levels, and to compare inflammatory markers in EAT in CAD and MS patients after S or P treatment.
Methods: In patients age 60±6,5 years, 65% male, eligible for coronary artery bypass grafting, biopsy specimens of EAT and blood were obtained. Twenty patients used S (20-40 mg/day) and 15 used only P (15-30 mg/day), both for 90 days before surgery, while 15 patients used neither S nor P (control). NCEP-ATP III criteria was used to MS diagnosis. The usual treatments were maintained. Plasma hsCRP levels were measured. EAT fragments were embedded in paraffin and serial sections were submitted to immunohistochemistry. The mean percentage positive area for CD68+ macrophages (M), tumor necrosis factor-α (TNFα), interleukin-6 (IL6), and adiponectin was obtained using the image analyzer Leica Quantimet 500. Data were compared by ANOVA.
Results: I nflammatory markers are in table 1 and correlation between hsCRP values and EAT M amount are in figure 1.
Conclusions: Simvastatin or pioglitazone therapy have concomitant anti-inflammatory effects on plasma and EAT and the high sensitivity C-reactive protein, a systemic marker, reflected changes upon EAT.
- © 2011 by American Heart Association, Inc.